Improved Measurement of Treatment Effect in Multiple Sclerosis Clinical Trials

Alessio Signori; Francesca Bovis; Maurizio Fedriga; Noemi Montobbio; Marta Ponzano; Irene Schiavetti; Maria Pia Sormani

doi:10.1001/jamaneurol.2024.4396

Improved Measurement of Treatment Effect in Multiple Sclerosis Clinical Trials

JAMA Neurol. 2024 Dec 23. doi: 10.1001/jamaneurol.2024.4396. Online ahead of print.

Authors

Alessio Signori^{1

2}, Francesca Bovis¹, Maurizio Fedriga¹, Noemi Montobbio¹, Marta Ponzano¹, Irene Schiavetti¹, Maria Pia Sormani^{1

2}

Affiliations

¹ Department of Health Sciences, University of Genoa, Genoa, Italy.
² IRCCS Ospedale Policlinico San Martino, Genova, Italy.

PMID: 39714836
DOI: 10.1001/jamaneurol.2024.4396

No abstract available

Plain language summary

This decision analytical applies restricted mean survival time as a measure of treatment effect in 2 randomized clinical trials assessing disease-modifying treatments vs placebo in patients with progressive multiple sclerosis.